FidoCure?

FidoCure CEO Christina Lopes recently reconnected with her former Columbia University Professor and Mastercard Chairperson, Merit Janow, at the 2024 Fortune Global Forum in New York City. Merit spoke as part of a panel discussion on “Adapting Business for a Global Landscape Shifting” with Zoetis CEO Kristin Peck, and other leaders in business. During the panel, Kristin highlighted pet oncology as a key therapeutic area for Zoetis and shared that half of the company's revenue comes from international markets. This discussion of the global demand for cancer therapeutics reinforces the importance of FidoCure's mission to improve canine cancer care with AI-driven precision medicine, addressing a significant unmet need worldwide. #FidoCure #FortuneGlobalForum #BusinessInsights #Cancer #Therapeutics #AI #AnimalHealth #PrecisionMedicine #Dogs

FidoCure is going global again! ?? We're excited to announce our participation in the 23rd Federation of Asian Veterinary Associations (FAVA) Congress in Korea, October 25-27, 2024. Dr. Lucas Rodrigues, our Head of Veterinary Research, will present twice tomorrow on October 26th, sharing insights on: 1. Decoding canine cancer: Exploring genetic alterations as a gateway to advancing cancer care in dogs 2. Small molecules for targeted therapy in canine cancer: How to implement in your practice? These presentations highlight our commitment to advancing precision veterinary medicine and sharing our AI-driven practices with the global veterinary community, to improve the quality of life for dogs battling cancer and supporting the families who care for them. https://hubs.li/Q02VRCvJ0 #FidoCure #VeterinaryOncology #FAVA2024 #PrecisionMedicine

We were delighted to be part of this year's Veterinary Cancer Society Annual Conference, which saw record-breaking attendance! This milestone reflects the tremendous interest and incredible progress being made in veterinary oncology. It was an honor to present our latest research on hemangiosarcoma at the conference. Contributing our findings helps expand the collective understanding and available treatments for this difficult disease. With the continued exploration of innovative approaches, including precision medicine for canine cancer, we are excited to be leading the way in developing advanced treatment options that will benefit pets and their families. Thank you for being part of this journey with us!

FidoCure will present important new findings on canine hemangiosarcoma (HSA) at the 2024 Veterinary Cancer Society (VCS) Annual Conference, October 17-19 at the Caribe Royale Orlando! This marks our continued leadership in the largest and most prestigious conference in the veterinary oncology field. Canine splenic hemangiosarcoma, a particularly aggressive cancer that originates in the spleen, is responsible for approximately 300,000 dog deaths annually in the U.S. At the conference, Dr. Lucas Rodrigues, FidoCure's Head of Veterinary Research, will unveil our latest findings on HSA. The study demonstrates that AI-driven precision oncology for dogs with splenic hemangiosarcoma yields outcomes that are comparable to, or even exceed, those achieved with standard adjuvant chemotherapy. Furthermore, we have pinpointed specific genetic mutations that are closely linked to prognosis, significantly advancing our understanding of canine HSA. Visit us at Booth 25 to learn how our data-driven approach and innovative therapies are enhancing treatment outcomes and quality of life for dogs with cancer. Discover how we're elevating the standard of care in veterinary oncology and developing first-class precision therapies for canine cancer. Learn more about the research. https://bwnews.pr/4eLGQYR #VeterinaryOncology #CanineCancer #PrecisionMedicine #VCS2024 #VeterinaryCancerSociety #FidoCure #Hemangiosarcoma

As National Veterinary Technician Week (October 13-19) approaches, FidoCure is excited to honor the invaluable role of veterinary technicians in the fight against cancer. Vet techs are true partners in care, providing support on both ends of the leash—offering expert care to dogs and emotional guidance to families navigating the cancer journey. We are incredibly grateful for their dedication and partnership as we continue our mission, having already helped over 5,000 dogs with cutting-edge, AI-driven precision medicine to receive advanced cancer care. Their compassion and expertise are essential to the progress we make every day. To celebrate, we invite you to nominate an outstanding veterinary technician who goes above and beyond in their role. They’ll have the chance to win: ? (1) Lunch for your team ($400 value) ? (1) $100 FIGS gift card ? (5) Personalized bandage scissors ? (10) $25 VISA gift card Let’s come together to recognize these professionals who are making a significant difference in the fight against pet cancer. Nominate your vet tech—or, if you're a vet tech, feel free to nominate yourself—by October 10th. Winners will be announced during Vet Tech Week! Submit your nomination today: https://hubs.li/Q02RStqc0 #FidoCure #VetTechWeek #VetTech #VetMed #DogsWithCancer #CancerCare #PetOncology

FidoCure is proud to see CEO Christina Lopes featured in the Columbia Women's Business Society newsletter, The Scope! ???? Christina Lopes shared insights into how FidoCure is leading the charge in veterinary oncology. As pioneers in canine precision medicine, FidoCure is leveraging AI and genomic sequencing to revolutionize cancer treatment for dogs. Key highlights from the feature include: - Our AI-driven approach has expanded to over 1,350 veterinary clinics worldwide - We've built the world's largest canine cancer dataset with over 2 billion data points - Our research is accelerating drug development for both canine and human cancers - We've recently won a patent for a novel AI-developed drug to fight canine cancer Read the full profile here: https://hubs.li/Q02QCsTP0 #VeterinaryOncology #PrecisionMedicine #AIinHealthcare #CanineCancer #WomenInSTEM

Thrive Pet Healthcare and FidoCure? are celebrating two years of groundbreaking collaboration, transforming canine cancer care through innovative precision medicine. This powerful partnership has already made a significant impact, with Thrive veterinarians utilizing FidoCure's cutting-edge AI-driven platform to treat approximately 400 canine cancer cases. The results are truly inspiring, offering new hope to countless pets and their families. Venya, a 13?-year-old German Shepherd, is one of those patients. She is our inspiration to push the boundaries of veterinary oncology as she thrives despite multiple cancer diagnoses. By combining FidoCure's advanced technology with Thrive's extensive network, we're not just changing lives - we're revolutionizing the future of veterinary oncology and contributing valuable insights to human cancer research. Here's to two years of progress and to the countless breakthroughs yet to come! https://lnkd.in/gZ67Wzrn #FidoCure #VeterinaryInnovation #CanineCancerCare #PrecisionMedicine #Dogs #CancerCare

FidoCure is proud to announce our recent participation in the prestigious Kansas City Animal Health Corridor Summit, where CEO Christina Lopes unveiled the world's first portfolio of de-risked canine cancer therapies. This groundbreaking presentation marks a significant milestone in our mission to revolutionize cancer care for dogs. We are honored to have been among the leading innovators in animal healthcare, showcasing our advancements alongside other cutting-edge companies pushing the boundaries of veterinary medicine. The summit was also an incredible opportunity to announce that FidoCure is expanding into drug development. This expansion will allow us to accelerate the development of more effective and accessible cancer treatments for dogs, bringing hope to countless families facing canine cancer. #VeterinaryMedicine #CanineCancer #AnimalHealth #Innovation #DrugDevelopment

We are so proud of our founder Christina Lopes for sharing her startup journey with BayBrazil at Coursera HQ. An impressive panel of industry leaders sharing their insights and experiences as Brazilian founders in Silicon Valley. #FidoCure #BrazilBay

We're excited to share that our Founder and CEO, Christina Lopes was recently featured in Forbes! In this interview, Christina discusses her journey in building FidoCure and how the company provides cutting-edge targeted therapies to dogs, from humans. As Christina explains, dogs naturally develop many of the same cancers as humans, but their smaller size and faster disease progression allow researchers to study the full cancer journey. By first focusing on developing cutting-edge cancer treatments for our canine companions, the FidoCure team is helping thousands of dogs battling cancer. And in the process, they are uncovering insights that could profoundly impact the fight against human cancer as well. Check out the full Forbes feature to learn more about Christina's vision for FidoCure and the potential of comparative oncology: https://hubs.li/Q02M70PK0 #FidoCure #CancerResearch #Dogs #ForbesFeature